Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of VVD-133214 plus pembrolizumab versus pembrolizumab alone in first-line MSI-H/dMMR advanced colorectal cancer
CTR20262977Phase 2Active
- Sponsor
- Bayer
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing VVD-133214 + pembrolizumab with Pembrolizumab monotherapy (2 arms). Primary endpoint: 6-month landmark progression-free survival rate. Started Jul 2026; status: active.
02
Drugs
VVD-133214pembrolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20262977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262977.